Le Registre des lobbyistes
AbbVie Corporation
| Objets | Détails | Catégories |
|---|---|---|
|
Santé, Industrie, Propriété intellectuelle, Commerce international
|
Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
|
Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
|
Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
|
Politique ou Programme, Règlement
|
|
Propriété intellectuelle, Commerce international
|
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
|
Règlement, Politique ou Programme
|
|
Relations fédérales-provinciales, Santé
|
Communications regarding national pharmacare legislation, regulations, policies or programs.
|
Proposition législative, Projet de loi ou résolution, Politique ou Programme, Règlement
|
|
Santé
|
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
|
Politique ou Programme
|
|
Santé
|
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
|
Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications with Health Canada regarding guidelines for pediatric action plans.
|
Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
|
Politique ou Programme, Règlement
|
|
Santé
|
Communications with Health Canada regarding the application of its nitrosamine guidelines.
|
Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
|
Règlement, Politique ou Programme
|
|
Santé, Recherche et développement
|
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
|
Politique ou Programme, Règlement
|
|
Santé, Commerce international
|
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
|
Politique ou Programme
|
|
Affaires autochtones, Santé
|
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
|
Politique ou Programme
|
|
Développement économique, Industrie, Recherche et développement
|
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
|
Politique ou Programme
|
|
Développement économique, Santé, Industrie, Propriété intellectuelle
|
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
|
Politique ou Programme
|
|
Affaires autochtones, Santé
|
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
|
Politique ou Programme
|
|
Santé
|
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
|
Politique ou Programme
|